Jane B. Trepel
#159,532
Most Influential Person Now
Jane B. Trepel's AcademicInfluence.com Rankings
Jane B. Trepelbiology Degrees
Biology
#12514
World Rank
#15995
Historical Rank
Molecular Biology
#2043
World Rank
#2075
Historical Rank
Biochemistry
#2142
World Rank
#2286
Historical Rank
Download Badge
Biology
Jane B. Trepel's Degrees
- PhD Biochemistry University of California, San Francisco
- Bachelors Biology Stanford University
Similar Degrees You Can Earn
Why Is Jane B. Trepel Influential?
(Suggest an Edit or Addition)Jane B. Trepel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Targeting the dynamic HSP90 complex in cancer (2010) (1360)
- HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. (2005) (889)
- IL‐1β mediated up‐regulation of HIF‐lα via an NFkB/COX‐2 pathway identifies HIF‐1 as a critical link between inflammation and oncogenesis (2003) (601)
- Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. (1996) (397)
- Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. (1996) (397)
- Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. (2005) (381)
- The hsp90-related Protein TRAP1 Is a Mitochondrial Protein with Distinct Functional Properties* (2000) (359)
- IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. (2003) (339)
- Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. (2013) (334)
- p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* (1998) (300)
- Curcumin is an inhibitor of p300 histone acetylatransferase. (2006) (285)
- Metastasis-associated differences in gene expression in a murine model of osteosarcoma. (2001) (283)
- Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway (1996) (280)
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. (2007) (273)
- Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. (1994) (254)
- Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. (1992) (239)
- Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275 (2004) (228)
- Taxol induction of p21WAF1 and p53 requires c-raf-1. (1995) (215)
- Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species (2009) (215)
- Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis (2013) (210)
- Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions (2001) (201)
- A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells (1997) (198)
- Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. (2015) (196)
- Characteristics of cell lines established from human gastric carcinoma. (1990) (193)
- p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. (1996) (192)
- The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. (2011) (186)
- Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. (2003) (186)
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations (2018) (186)
- Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21 WAF1/CIP1 in Human Prostate Carcinoma Cells* (1998) (172)
- Impact of extracellular folate levels on global gene expression. (2001) (170)
- Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. (2010) (168)
- Regulation of Cyclin D1 by Calpain Protease* (1997) (166)
- Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. (2011) (155)
- Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity (2017) (152)
- Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. (2011) (146)
- Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. (2002) (145)
- Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. (2010) (140)
- Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling (2001) (140)
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study (2018) (133)
- Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. (1991) (131)
- MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. (2001) (130)
- Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells (2011) (127)
- Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies (2007) (127)
- Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. (1995) (125)
- STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. (2010) (120)
- A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas (2011) (113)
- Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. (2012) (113)
- Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. (2019) (109)
- A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer (2017) (108)
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma (2014) (106)
- Phorbol ester induces c-sis gene transcription in stem cell line K-562 (1986) (103)
- A phase II study of perifosine in androgen independent prostate cancer (2005) (101)
- Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. (2014) (99)
- Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. (2014) (98)
- Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. (2003) (96)
- DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells (2003) (95)
- The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. (2003) (93)
- Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. (2004) (93)
- Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone (2008) (93)
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. (2017) (92)
- P2-purinergic receptor agonists inhibit the growth of androgen-independent prostate carcinoma cells. (1992) (92)
- Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. (2004) (90)
- Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. (1992) (89)
- Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. (2002) (89)
- Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors. (2018) (88)
- c-Met Ectodomain Shedding Rate Correlates with Malignant Potential (2006) (87)
- Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2 (2002) (86)
- Microtubule Disruption Utilizes an NFκB-dependent Pathway to Stabilize HIF-1α Protein* (2003) (86)
- Transcriptional Regulation of the Transforming Growth Factor β Type II Receptor Gene by Histone Acetyltransferase and Deacetylase Is Mediated by NF-Y in Human Breast Cancer Cells* (2002) (85)
- Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription. (2001) (84)
- Hsp90 charged-linker truncation reverses the functional consequences of weakened hydrophobic contacts in the N domain (2009) (82)
- A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells. (1992) (81)
- Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development (2018) (80)
- Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. (2018) (79)
- The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. (1999) (78)
- Temozolomide in the Era of Precision Medicine. (2017) (78)
- Bombesin-related peptides induce calcium mobilization in a subset of human small cell lung cancer cell lines. (1987) (77)
- Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells (2004) (76)
- A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. (1988) (73)
- MGMT Status as a Clinical Biomarker in Glioblastoma. (2020) (73)
- Heat shock protein 90α (HSP90α), a substrate and chaperone of DNA-PK necessary for the apoptotic response (2012) (72)
- Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1 (1998) (72)
- Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. (2009) (72)
- A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study (2014) (72)
- Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. (2013) (70)
- Regulation of BRCA1 by protein degradation (1999) (70)
- Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug (2003) (70)
- Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma (2015) (70)
- Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-l-integrin (1996) (69)
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses (2019) (69)
- HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation (2017) (68)
- Cyclic AMP induces transforming growth factor beta 2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. (1992) (66)
- Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma (2017) (65)
- Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies (1989) (64)
- Histone deacetylase inhibitors in cancer therapy (2008) (64)
- Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies. (2016) (62)
- High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer (2019) (61)
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors (2020) (60)
- Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer (2008) (60)
- Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy (2020) (60)
- Transferrin receptor expression and the control of cell growth. (1986) (58)
- Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. (1986) (58)
- Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. (1998) (56)
- CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential (2002) (56)
- In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome (1998) (55)
- Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity. (2013) (55)
- Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. (2021) (55)
- Bombesin and Gastrin-Releasing Peptide: Neuropeptides, Secretogogues, and Growth Factors (1990) (54)
- Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity (2011) (54)
- c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells (2015) (54)
- Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. (2013) (54)
- Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA* (2009) (53)
- Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors (2018) (53)
- The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. (2013) (52)
- Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells (1987) (50)
- Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells (2005) (50)
- Transcriptional Activation of p21WAF1/CIP1 by Apicidin, a Novel Histone Deacetylase Inhibitor☆ (2001) (50)
- The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat (2016) (50)
- The detergent Triton X‐100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte‐induced apoptosis (1994) (50)
- Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors (2016) (49)
- Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small-cell lung-cancer cell line. (1988) (48)
- Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer (2016) (48)
- A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer (2015) (48)
- Stressing the Development of Small Molecules Targeting HSP90 (2013) (47)
- p185 Binds to GRP94 in Vivo (1996) (46)
- DNA methyltransferase 1 and 3B activate BAG-1 expression via recruitment of CTCFL/BORIS and modulation of promoter histone methylation. (2008) (43)
- Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. (2003) (43)
- Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors (2015) (43)
- Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants (2015) (42)
- Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma. (2014) (42)
- Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. (2020) (42)
- Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer (2021) (42)
- RNA sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. (2019) (41)
- Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. (2007) (41)
- A Phase II Clinical Trial of TRC105 (Anti‐Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma (2017) (41)
- Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical gamma isoform of protein kinase C does not confer increased resistance to doxorubicin. (1992) (41)
- Immunotherapy: a new treatment paradigm in bladder cancer (2017) (40)
- RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials (2017) (39)
- Expression of the B-Cell Receptor Component CD79a on Immature Myeloid Cells Contributes to Their Tumor Promoting Effects (2013) (39)
- Ex Vivo Rapamycin Generates Apoptosis-Resistant Donor Th2 Cells That Persist In Vivo and Prevent Hemopoietic Stem Cell Graft Rejection1 (2008) (39)
- SIRT2 Interacts with β-Catenin to Inhibit Wnt Signaling Output in Response to Radiation-Induced Stress (2014) (39)
- A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib (2015) (38)
- Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics (2017) (37)
- Transfer of ADP-ribose from NAD to choleragen: a subunit acts as catalyst and acceptor protein. (1977) (36)
- A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. (2018) (36)
- 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. (2017) (36)
- Cancer vaccine strategies: translation from mice to human clinical trials (2018) (35)
- Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. (2013) (35)
- KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. (2008) (35)
- Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. (1993) (34)
- Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint (2000) (34)
- In vitro enhancement of immunoglobulin gene expression in chronic lymphocytic leukemia. (1984) (33)
- Ras, ROS and proteotoxic stress: a delicate balance. (2011) (33)
- A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. (2020) (32)
- Hsp90 middle domain phosphorylation initiates a complex conformational program to recruit the ATPase-stimulating cochaperone Aha1 (2019) (31)
- Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy (2020) (30)
- Identification of endogenously S-nitrosylated proteins in Arabidopsis plantlets : Effect of cold stress on cysteine nitrosylation level (2014) (30)
- Serotonin concentrations in brain and blood of scrapie-infected and normal hamsters and mice (1981) (29)
- Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas. (2019) (29)
- Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung (2018) (29)
- Peptide Growth Factors and Their Receptors II (1990) (29)
- Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease (1999) (28)
- An Hsp90 co-chaperone protein in yeast is functionally replaced by site-specific posttranslational modification in humans (2017) (28)
- Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma (2019) (28)
- Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation (2019) (28)
- Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells. (1994) (28)
- TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer (2016) (28)
- A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). (2018) (28)
- Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48‐hour continuous infusion in patients with cancer (2016) (27)
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas (2013) (27)
- Emerging immunotherapies for bladder cancer (2015) (27)
- Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. (2001) (27)
- Chromosomal protein HMGN1 modulates the expression of N‐cadherin (2005) (26)
- Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma (2013) (26)
- E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M. (2004) (26)
- STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma (2016) (25)
- E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group (2021) (25)
- CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer (2015) (25)
- Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis (2019) (24)
- Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. (2005) (24)
- Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells (2012) (24)
- Effect of interferons on protein synthesis in human lymphocytes: enhanced synthesis of eight specific peptides in T cells and activation-dependent inhibition of overall protein synthesis. (1982) (23)
- RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer (2019) (23)
- Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer (2016) (22)
- Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. (2011) (22)
- Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. (1991) (22)
- Significant non-S-phase DNA synthesis visualized by flow cytometry in activated and in malignant human lymphoid cells. (1985) (21)
- Regulation of actin cytoskeleton in lymphocytes: PKC‐δ disrupts IL‐3–induced membrane ruffles downstream of Rac1 (1999) (21)
- Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells. (1992) (21)
- EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models (2016) (21)
- Autocrine growth factors and lung cancer. (1989) (21)
- Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer (2018) (19)
- Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. (1999) (19)
- Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines. (1998) (19)
- Pharmacodynamic assessment of histone deacetylase inhibitors: infrared vibrational spectroscopic imaging of protein acetylation. (2008) (19)
- Diltiazem inhibits transferrin receptor expression and causes G1 arrest in normal and neoplastic T cells (1986) (19)
- The beta subunit of the interleukin-2 receptor mediates interleukin-2 induction of anti-CD3 redirected cytotoxic capability in large granular lymphocytes. (1988) (18)
- Methoxychalcone inhibitors of androgen receptor translocation and function. (2012) (18)
- Taxol Induction of @ 21 wAF 1 and p 53 Requires c-raf-1 (18)
- Phorbol ester enhances deoxynucleoside incorporation while inhibiting proliferation of K-562 cells. (1985) (18)
- A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC). (2017) (18)
- Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study (2020) (18)
- Emetine Promotes von Hippel-Lindau-Independent Degradation of Hypoxia-Inducible Factor-2α in Clear Cell Renal Carcinoma (2010) (17)
- Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma (2018) (17)
- Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells. (1993) (17)
- Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators. (2013) (16)
- Monoamine oxidase activity in the cardiovascular system of young and aged rats (1977) (16)
- Immunotherapies for bladder cancer: a new hope (2015) (16)
- Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer (2015) (16)
- UGT1A1 genotype‐dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation (2016) (16)
- Human T lymphotropic virus I infection deregulates surface expression of the transferrin receptor. (1988) (15)
- Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC). (2017) (15)
- PC12 cells regulate inducible cyclic AMP (cAMP) element repressor expression to differentially control cAMP response element‐dependent transcription in response to nerve growth factor and cAMP (2006) (15)
- Modulation of prion protein structural integrity by geldanamycin. (2003) (14)
- Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells. (2016) (14)
- Effect of guanine and adenine nucleotides on bombesin-stimulated phospholipase C activity in membranes from Swiss 3T3 and small cell lung carcinoma cells. (1990) (14)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (14)
- Gastrin-releasing peptide and other autocrine growth factors in lung cancer: pathogenetic and treatment implications. (1988) (13)
- Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors (2022) (12)
- Assays for pharmacodynamic analysis of histone deacetylase inhibitors (2006) (12)
- Anticancer drugs-induced apoptotic cell death in leukemia cells is associated with proteolysis of β-catenin (2002) (12)
- Nuclear β-catenin displays GSK-3β- and APC-independent proteasome sensitivity in melanoma cells (2000) (12)
- High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). (2019) (12)
- A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001 (2016) (12)
- The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury (2017) (11)
- Histone deacetylase inhibitors induce apoptosis with minimal viral reactivation in cells infected with Kaposi's sarcoma-associated herpesvirus. (2006) (11)
- Rapid turnover and impaired cell-surface expression of the human folate receptor in mouse L(tk-) fibroblasts, a cell line defective in glycosylphosphatidylinositol tail synthesis. (1995) (11)
- Ganetespib, an HSP90 inhibitor, kills Epstein–Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood (2017) (10)
- Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses (2020) (10)
- Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor κ B activation (10)
- Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. (2015) (10)
- High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma (2014) (10)
- Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer (2020) (10)
- Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. (2016) (9)
- The Heat Shock Protein 90 Inhibitor Geldanamycin and the ErbB Inhibitor ZD 1839 Promote Rapid PP 1 Phosphatase-Dependent Inactivation of AKT in ErbB 2 Overexpressing Breast Cancer Cells (2003) (9)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (9)
- A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. (2013) (9)
- A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer (2015) (9)
- c-myc Down-regulation in suramin-treated HL60 cells precedes growth inhibition but does not trigger differentiation. (1994) (9)
- A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC). (2014) (8)
- Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors. (2021) (8)
- Site-directed mutagenesis of tryptophan residues to conserved hydrophobic residues inhibits the processing of human KB cell folate receptor. (1994) (8)
- Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (8)
- Mps 1 Mediated Phosphorylation of Hsp 90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp 90 Inhibitors Graphical (2016) (7)
- Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer (2021) (7)
- HSP 90 inhibitors disrupt a transient HSP 90-HSF 1 interaction and identify a noncanonical model of HSP 90-mediated HSF 1 regulation (2018) (7)
- In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit (2021) (7)
- Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc (2019) (7)
- Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors (2020) (7)
- Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein. (2013) (7)
- Hsp 90 middle domain phosphorylation initiates a complex conformational program to recruit the ATPase stimulating cochaperone Aha (2019) (7)
- NAD glycohydrolase: enzyme characterization using intact mammalian erythrocytes. (1982) (7)
- Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer (2020) (6)
- Phase II study of cixutumumab (IMC-A12) in thymic malignancies. (2012) (6)
- p185 erbB2 Binds to GRP94 in Vivo DISSOCIATION OF THE p185 erbB2 /GRP94 HETEROCOMPLEX BY BENZOQUINONE ANSAMYCINS PRECEDES DEPLETION OF p185 erbB2 * (1996) (6)
- RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor (2017) (6)
- A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase‐Clinical Trial Network (PEP‐CTN) (2021) (5)
- Megakaryocyte differentiation: studies at the molecular level using the K-562 cell line. (1986) (5)
- Anticancer-drug-induced apoptotic cell death in leukemia cells is associated with proteolysis of beta-catenin. (2002) (5)
- Phase l study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors. (2012) (5)
- Inhibitors of bombesin-stimulated intracellular signals: interruption of an autocrine pathway as a therapeutic strategy in small cell lung carcinoma. (1990) (5)
- A Link Between Histone Deacetylase Inhibitors and NF-kappaB Signaling (2003) (5)
- Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies (2021) (5)
- Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. (2019) (5)
- Pharmacologic dissection of the overlapping impact of heat shock protein family members on platelet function (2020) (5)
- Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy (2022) (5)
- Biomarker correlates from the randomized phase 2 trial of the PARP inhibitor olaparib (O) with or without the antiangiogenic TKI cediranib (C) in recurrent platinum-sensitive ovarian cancer (NCT01116648). (2014) (4)
- Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. (2021) (4)
- Genes expressed selectively in murine and human plasma cell neoplasms. (1995) (4)
- Ion channels as molecular targets in prostate cancer. (2003) (4)
- Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy (2018) (4)
- Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells. (2017) (4)
- Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study (2019) (4)
- Phase I trial of the oral histone deacetylase inhibitor MS-275 administered with food. (2006) (4)
- Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors. (2019) (3)
- MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays (2022) (3)
- Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor (2005) (3)
- Differential distribution of type A and B monoamine oxidase in neuronal tissues. (1977) (3)
- OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma (2017) (3)
- Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group (2021) (3)
- Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. (2021) (3)
- A Phase II Trial of IPH2101 (anti-KIR mAb) in Smoldering Multiple Myeloma (2011) (3)
- Targeting Histone Deacetylase as a Strategy for Cancer Prevention (2004) (3)
- A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer. (2019) (3)
- Cabozantinib and peripheral immunity in advanced urothelial carcinoma: Final results from an open-label, phase II trial (2021) (3)
- Post-translational modification and conformational state of Heat Shock Protein 90 differentially affect binding of chemically diverse small molecule inhibitors (2013) (3)
- Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (3)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- Posttranslational Control of Beta-Catenin Signaling Regulates Peripheral Blood Lymphocyte Activation. (2005) (2)
- Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma (2020) (2)
- A phase I study of TRC105 (anti-CD105 monoclonal antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2011) (2)
- Abstract 966: Phase II clinical trial patient responses to the macrophage activating agent RRx-001 correlate to TGF- β pathway activation and markers for fibrosis (2017) (2)
- Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair–deficient tumors (2020) (2)
- Down-Regulation of Promyelocytic Cell Transferrin Receptor Expression by Cholera Toxin and Cyclic Adenosine Monophosphate (1986) (2)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer. (2021) (2)
- Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling (2021) (2)
- Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). (2013) (2)
- A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas. (2022) (2)
- Phase I study of vandetanib (V) and bevacizumab (B) combination therapy evaluating the VEGF and EGF signal transduction pathways in adults with solid tumors and NHL. (2016) (2)
- A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2014) (2)
- Therapeutics , Targets , and Chemical Biology The HSP 90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and-Resistant MET-Driven Tumor Models (2013) (2)
- Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1 (cid:2) Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species (cid:1) (2009) (2)
- Abstract A004: HER2 cancer vaccine phase I clinical trial shows clinical benefit in 54% of evaluable patients (2019) (2)
- Randomized phase II clinical trial to assess MUC1 specific immune response to L-BLP25 vaccine in addition to standard therapy in newly diagnosed high-risk prostate cancer. (2012) (1)
- Nuclear β-Catenin Signaling as a Target for Anticancer Drug Development (2002) (1)
- Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (1)
- Cell microarray platform for anticancer drug development (2007) (1)
- Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi). (2019) (1)
- Abstract 5000: Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrentBRCAwild-type high-grade serous ovarian cancer (HGSOC) patients (2019) (1)
- Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma (2019) (1)
- Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. (2020) (1)
- RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization (2017) (1)
- Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). (2016) (1)
- 664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors (2021) (1)
- Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results. (2015) (1)
- A phase II study of TR105 in patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib. (2013) (1)
- Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2012) (1)
- Antimetastatic activity of ganetespib: Preclinical studies and assessment of progressions due to new lesions in the GALAXY-1 NSCLC trial. (2013) (1)
- 343 Novel role of fumarate in antagonizing VHL function (2004) (1)
- Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial (2018) (1)
- Abstract PO-054: A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP) (2021) (1)
- Cytotoxicity and metabolism of 4-methoxy-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine in HCT 116 colon cancer cells. (1994) (1)
- Abstract 959: Targeting renal cell carcinoma with englerin A (2011) (1)
- A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC). (2013) (1)
- inhibitor, in adults with refractory and relapsed acute leukemias Phase 1 and pharmacologic study of MS-275, a histone deacetylase (2013) (1)
- Early biomarkers of response to carfilzomib in multiple myeloma (MM): Modulation of CXCR4 and induction of autophagy. (2014) (1)
- TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib. (2014) (1)
- Gene expression changes during hormonal therapy for prostate cancer reveal candidate diagnostic and drug targets (2001) (1)
- Human Breast Cancer Cells Type II Receptor Expression in β Transforming Growth Factor MS-275 , A Histone Deacetylase Inhibitor , Selectively Induces Updated (2001) (0)
- Modulation ofbombesin-induced phosphatidylinositol hydrolysis ina small-cell lung-cancer cell line (1988) (0)
- Preliminary association of circulating tumor cells (CTCs) pre- and post-AdHER2 dendritic cell vaccination with overall survival in patients with metastatic HER2+ solid tumors (2015) (0)
- Abstract 5291: Exploring mechanisms underlying invasion in HLRCC: Assessing the contribution of HIF and ROS (2010) (0)
- P3.04-27 An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study (2018) (0)
- 143 The interferon-inducible GTPase MxA is a metastasis suppressor (2004) (0)
- The use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase as a cancer treatment way (1993) (0)
- The Use of Histone Deacetylase Inhibitors for the Treatment of Solid Tumors (2007) (0)
- Hsp90 middle domain phosphorylation initiates a complex conformational program to recruit the ATPase-stimulating cochaperone Aha1 (2019) (0)
- Phase II Evaluation of an Allogeneic Tumor Cell Lysate Vaccine with or without Metronomic Oral Cyclophosphamide and Celecoxib in Patients with Thoracic Malignancies (2017) (0)
- MP49-03 CIRCULATING TUMOR CELL SUBTYPES AND BASELINE T-CELL POPULATION AS PROGNOSTIC BIOMARKERS TO COMBINATION THERAPY WITH CABOZANTINIB, NIVOLUMAB, AND IPILIMUMAB IN METASTATIC GENITOURINARY CANCER PATIENTS (2020) (0)
- Beta-Catenin and Leukemic Cell Apoptosis (2000) (0)
- 1333 LACK OF IMPACT OF ROBOTIC-ASSISTED RADICAL PROSTATECTOMY ON CIRCULATING TUMOR CELL LEVELS IN PATIENTS WITH CLINICALLY LOCALIZED PROSTATE CANCER (2013) (0)
- Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development (2018) (0)
- Abstract B206: Pharmacokinetic and pharmacodynamic analysis of patients treated with the histone deacetylase inhibitor entinostat in combination with erlotinib (2009) (0)
- Consequences of adenovirus-mediated p16 protein expression on cell cycle arrest are determined by the endogenous Rb status in human cancer cells (1997) (0)
- Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel (2022) (0)
- Inhibition of Immunoglobulin Secretion, But Not Immunoglobulin Synthesis, by a Monoclonal Antibody (1986) (0)
- Abstract A030: Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial (2016) (0)
- 124 MULTIPARAMETER FLOW CYTOMETRIC ANALYSIS OF RENAL CELL CARCINOMA TUMOR MICROENVIRONMENT (2011) (0)
- Abstract B001: Preliminary clinical activity and safety of an autologous AdHER2 dendritic cell vaccine in patients with advanced metastatic HER2+ solid tumors (2016) (0)
- Abstract 1562: Correlative biomarker analysis of the phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in BRCA wild-type (BRCAwt), platinum-resistant recurrent, high-grade serous ovarian cancer (PR-HGSOC) (2023) (0)
- Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer (2015) (0)
- Rapid Publications In Vitro Enhancement of Immunoglobulin Gene Expression in Chronic Lymphocytic Leukemia (2013) (0)
- P2.04-019 A Peripheral Immune Signature Associated with Clinical Activity of Sunitinib in Thymic Carcinoma: Topic: Thymic Malignancies Clinical and Translational (2017) (0)
- Peptide-induced mRNAs in whole blood ex vivo as a unique assay for peptide-specific T cell immunity (2013) (0)
- Emetine promotes VHL-independent inhibition of hypoxia-inducible factor-2alpha in a renal carcinoma cell line (2008) (0)
- Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high-grade serous ovarian cancer (HGSOC) (2014) (0)
- Beta-catenin signaling regulates acute adult T-cell leukemia/lymphoma (2007) (0)
- Control of the retinoblastoma family of cell-cycle regulatory proteins by an inhibitor of the mevalonate pathway (1997) (0)
- OncologyBranch,CenterforCancerResearch,NCI,NationalInstitutesofHealth,Bethesda,Maryland20892and**AivogenAG, BaselCH-4052,Switzerland (2009) (0)
- Distinct immune characteristics in women with deleterious germline BRCA1/2 mutations (gBRCAm)-associated high-grade serous ovarian cancer (HGSOC) (2015) (0)
- Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial. (2022) (0)
- Abstract LB-244: Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors (2018) (0)
- Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial. (2020) (0)
- A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC). (2015) (0)
- Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer A C (2021) (0)
- Reductase inhibitors employing 3-hydroxy-3-methylglutaryl coenzyme to as a modality for cancer therapy. (1993) (0)
- P2.06-031 QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets: Topic: Supportive, Preventive (2017) (0)
- Abstract 2901: Identifying synthetic lethal interactions in castration-resistant prostate cancer using HSP40 and HSP70 inhibitors (2018) (0)
- Evaluation of a new circulating tumor cell (CTC) platform to predict response and survival in metastatic urothelial carcinoma (UC) patients receiving cabozantinib (cabo). (2015) (0)
- A phase I study of gemcitabine, carboplatin, and lenalidomide for treatment of patients with advanced/metastatic urothelial carcinoma (UC) and other solid tumors. (2014) (0)
- CHAPTER 12:The Cancer Super-chaperone Hsp90: Drug Targeting and Post-translational Regulation (2013) (0)
- Novel Mechanism of Activated FLT3-Associated Leukemogenisis: FLT3 Regulates Wnt Signaling by Phosphorylating β-Catenin and Promoting β-Catenin Nuclear Localization. (2005) (0)
- RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer (2019) (0)
- Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). (2015) (0)
- C-105 Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase I study (2019) (0)
- CellMinerCDB: NCATS is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations. (2023) (0)
- DNA Damage and Repair SIRT 2 Interacts with b-Catenin to Inhibit Wnt Signaling Output in Response to Radiation-Induced Stress (2014) (0)
- Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics (2017) (0)
- Abstract CT113: A phase II study of prexasertib, a cell cycle checkpoint kinase 1 (CHK1) inhibitor, in platinum-resistant recurrent high-grade serous ovarian cancer (HGSOC) with BRCA wild-type (BRCAwt) (2022) (0)
- Thermal ablation for treatment of hepatic metastasis from thymic epithelial tumors (TETs). (2017) (0)
- 1331 PHENFORMIN INDUCES METABOLIC SHIFT OF PROSTATE CANCER CELLS TOWARDS UTILIZATION OF FATTY ACID METABOLISM (2013) (0)
- The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting (2013) (0)
- Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets (2018) (0)
- Myeloperoxidase is involved in Vincristine resistance in human myeloblastic leukemia (1994) (0)
- The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven tumor models (2013) (0)
- Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial (2023) (0)
- UGT1A1 genotype effects on PK, PD and toxicities of belinostat administered by 48 h continuous infusion. (2015) (0)
- Abstract 1180: Targeting the HSP40/HSP70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer (2017) (0)
- MPA PASS Enables Stitched Multiplex Multi-Dimensional EV Repertoire Analysis (2021) (0)
- factor-2 in clear cell renal carcinoma (2010) (0)
- Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors. (2017) (0)
- Stem Cell Graft Rejection Persist In Vivo and Prevent Hemopoietic Apoptosis-Resistant Donor Th 2 Cells That Ex Vivo Rapamycin Generates (2007) (0)
- A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia (2013) (0)
- Cell Stress Society International VIII INTERNATIONAL SYMPOSIUM ON HEAT SHOCK PROTEINS IN BIOLOGY AND MEDICINE: STRESS RESPONSES IN HEALTH & DISEASE (2016) (0)
- NOVEL THERAPIES TARGETING ANDROGEN RECEPTOR VARIANTS IN AN IN VITRO MODEL OF CASTRATE RESISTANT PROSTATE CANCER: MP57‐04 (2017) (0)
- HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation (2018) (0)
- Utilisation d'inhibiteurs de la 3-hydroxy-3-methylglutaryl coenzyme a-reductase comme methode de traitement du cancer (1993) (0)
- Transfer ofADP-ribose fromNAD tocholeragen: A subunit actsas catalyst andacceptor protein (1977) (0)
- Response to Radiation-Induced Stress-Catenin to Inhibit Wnt Signaling Output in β SIRT 2 Interacts with Updated (2014) (0)
- A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (0)
- ADDITIONS AND CORRECTIONS (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jane B. Trepel?
Jane B. Trepel is affiliated with the following schools:
